Fargeot, Guillaume <br/><br/>
Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.  [electronic resource] 

 -  Journal of neurology, neurosurgery, and psychiatry  07 2020 
 - 786-788 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1468-330X 
<br/><br/><label>Standard No.: </label>10.1136/jnnp-2020-323124  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Brentuximab Vedotin--adverse effects<br/>Female<br/>Guillain-Barre Syndrome--chemically induced<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating--chemically induced<br/>Young Adult